Winning approval for a new molecular entity is just a staging post on the journey of a drug. To maximize the benefits of a therapy, drugmakers need to continue trying to improve the product life cycle and reach more patients after winning first approval. The formulation development experts at Piramal Pharma Solutions discuss the options available to companies during the poet-approval period to make patient-centric improvements that enhance safety, effectiveness, convenience and access. This paper also looks at the CDMOs valuable role in R&D, manufacturing, and intellectual property protection.
